Baseline aspartate aminotransferase/alanine transaminase ratio is associated with 3-year mortality in peritoneal dialysis patients  

作　　者：Ruoxi Liao Xueli Zhou Dengyan Ma Jing Tang Hui Zhong 

机构地区：[1]Department of Nephrology,West China Hospital,Sichuan University,Chengdu,Sichuan 610041,China.

出　　处：《Chinese Medical Journal》2022年第13期1622-1624,共3页中华医学杂志（英文版）

基　　金：funded by the National Natural Science Foundation of China(No.82000702).

摘　　要：To the Editor:Peritoneal dialysis(PD)is a well-established renal replacement therapyin end-stage renal disease(ESRD)patients.Despite significant advances in technologies in recent decades,the mortality of PD patients remains high.Identifying prognostic factors for PD patients may help to identify patients at high risk.The aspartate aminotransferase(AST)/alanine transaminase(ALT)ratio was originally proposed as a marker of hepatic diseases.In recent years,researchers have found this ratio to be related to morbidity and mortality in other populations as well.[1,2]Therefore,we conducted this study to evaluate the prognostic value of the aspartate aminotransferase/alanine transaminase ratio(AST/ALT)ratio in PD patients.

关 键 词：patients DIALYSIS ASPARTATE 

分 类 号：R692.5[医药卫生—泌尿科学]